Definium Therapeutics (NASDAQ:DFTX) Reaches New 12-Month High – Here’s Why

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $47.20 and last traded at $46.81, with a volume of 3469289 shares changing hands. The stock had previously closed at $44.95.

Analyst Ratings Changes

DFTX has been the topic of a number of recent research reports. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. JonesTrading increased their target price on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. HC Wainwright lifted their price target on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, Canaccord Genuity Group set a $60.00 price target on Definium Therapeutics in a research report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $47.08.

Definium Therapeutics Stock Performance

The business’s 50-day moving average price is $24.59 and its 200-day moving average price is $19.41. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a market cap of $4.64 billion, a PE ratio of -18.69 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, equities research analysts expect that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,096 shares of company stock valued at $2,165,763 over the last three months. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DFTX. Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after acquiring an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of Definium Therapeutics during the fourth quarter valued at about $117,000. FNY Investment Advisers LLC purchased a new position in shares of Definium Therapeutics in the 3rd quarter valued at approximately $107,000. Finally, Caxton Associates LLP purchased a new position in shares of Definium Therapeutics in the 3rd quarter valued at approximately $126,000. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.